NCT01575522View on ClinicalTrials.gov

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativeRecurrent Breast CarcinomaStage IV Breast CancerTriple-Negative Breast Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Tivantinib

Given PO

Trial Locations (2)

02130

Dana-Farber Cancer Institute Faulkner Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01575522 - Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter